Importantly, the finding of our recent study [39] demonstrated that peripheral blood-derived CD34+ cell therapy significantly improved angina, heart failure and left ventricular function, supporting our hypothesis that CD34+ cell therapy might be beneficial to CKD patients with endothelial cell dysfunction. Here, CD34 is linked to angina pectoris.